ArticleAmerican journal of translational research2026
5-ALA-PDT combined with oral Kangfuxin solution improves HR-HPV outcomes, vaginal microecology and quality of life in patients with HPV-positive cervical erosion.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy, safety, and effects on related indicators of 5-aminolevulinic acid-mediated photodynamic therapy (5-ALA-PDT) combined with oral Kangfuxin liquid in patients with human papillomavirus (HPV)-positive cervical erosion.
methodsPatients admitted retrospectively from January 2022 to December 2024 were included. A total of 314 patients were initially screened, and 32 were excluded, leaving an original cohort of 282 patients (129 in the observation group and 153 in the control group). After propensity score matching (PSM) at a 1:1 ratio, 226 patients were included (113 in each group). This study compared clinical efficacy, cervical erosion grading, high-risk human papillomavirus (HR-HPV) seroconversion and re-seroconversion, gut microbiota, inflammatory factors, and scores on the 36-Item Short Form Health Survey (SF-36). Adverse reactions were also recorded, and multivariate logistic regression was performed.
resultsThe total effective rate was 96.46% in the observation group and 80.53% in the control group (P<0.001); the improvement in erosion grading was more significant (P<0.001). The HR-HPV seroconversion rates at 3 months were 80.5% and 63.7% (P=0.004), and the re-seroconversion rates at 6 months were 7.7% and 26.4% (P=0.001). After treatment, the vaginal pH was 4.25±0.21 and 4.39±0.30 (P<0.001), and the proportion of vaginal cleanliness grades I-II increased from 30.97% to 97.35% (P<0.001). Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and C-reactive protein (CRP) levels all decreased, with even lower levels in the observation group (all P<0.001); SF-36-related dimensions increased, with greater improvement in the observation group (all P<0.001).
conclusionCombining 5-ALA-PDT with oral Kangfuxin liquid can improve clinical efficacy and HR-HPV seroconversion rate, reduce recurrence, and improve microecology, inflammation, and quality of life, with comparable safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.